Fenwick Represents Merck Global Health Innovation Fund in Investment in Prognos Health’s $23 Million Financing

Fenwick represented Merck Global Health Innovation Fund, corporate venture capital arm of Merck, in its investment in Prognos Health’s $23 million financing. The round was co-led by Marshall Wace and Safeguard Scientifics with additional participation from Cigna Ventures, Hikma Ventures, Hunt Holdings, Labcorp, Maywic and Red and Blue Ventures.

Prognos will use this funding to accelerate their growth and expand the reach of their platform, bringing the benefits of integrated real-world data to even more healthcare organizations. More information can be obtained from the company’s announcement.

The transaction was led by corporate partners Ian Goldstein and Ryan McRobert and associate Joon Hwan Kim.